Kymera Therapeutics (KYMR) is down -9.2%, or -$8.64 to $85.66.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $116 from $80 at Truist
- Kymera Therapeutics’ KT-621: Promising Oral Treatment for Atopic Dermatitis and Asthma Expansion Potential
- Kymera Therapeutics price target raised to $134 from $84 at H.C. Wainwright
- Kymera Therapeutics price target raised to $120 from $67 at Oppenheimer
- Kymera Therapeutics price target raised to $127 from $73 at Morgan Stanley